Chonluten

Chonluten is a short synthetic peptide from the Russian 'Khavinson' bioregulator family, marketed for the lungs and airway lining, and derived from bronchial epithelial cells. In lab studies on immune cells it reduced production of the inflammatory signal TNF after a bacterial trigger, a finding cited as evidence for the broader idea that these short peptides can calm inflammation in their matching tissue. The evidence is Russian, limited to cell studies rather than human trials, hasn't been independently replicated, and Chonluten isn't FDA-approved.

Chonluten is marketed as a lung "bioregulator." In a cell-line study of several related peptides, the Chonluten tripeptide reduced production of the inflammatory signal TNF in immune cells exposed to a bacterial trigger — a laboratory finding consistent with a broad tissue-specific peptide theory. There are no large controlled human trials showing Chonluten treats any condition.

Not a drug in the US and not FDA-approved for any indication. A synthetic "Khavinson" short-peptide bioregulator ("cytogen") from the St. Petersburg Institute of Bioregulation and Gerontology (Russia), derived from bronchial epithelial cells. Evidence is almost entirely preclinical (cell studies) plus small Russian studies; no large controlled human trials. WADA: not specifically named; best treated as S0 (non-approved), prohibited at all times — verify with your anti-doping organization. Not DEA-scheduled.

Chonluten has essentially no controlled human safety data. It is not FDA-approved and is not a treatment for any inflammatory or lung condition. As a non-approved research peptide it is best treated as prohibited in regulated sport (WADA S0). VialWise is a research and educational reference, not medical advice.

⚠️ For research and educational purposes only. Chonluten is not FDA-approved and is not a treatment for any inflammatory or lung condition. Its evidence is preclinical. Information here is informational, not medical advice.

⚠️ Part of the Khavinson "bioregulator" family — read the shared caveat. Chonluten is one of a set of short peptides from the St. Petersburg Institute of Bioregulation and Gerontology. The whole family shares a thin, mostly-preclinical, largely single-institute evidence base and no large controlled human trials.[²]

Chonluten is a synthetic tripeptide (reported sequence Glu-Asp-Gly) in the "Khavinson" short-peptide bioregulator family, derived from bronchial epithelial cells. According to PubMed, a study of several Khavinson peptides in the human THP-1 monocyte/macrophage cell line found that the Chonluten tripeptide inhibited TNF production in immune cells exposed to bacterial lipopolysaccharide (LPS), and — with the other peptides tested — reduced pro-inflammatory IL-6 and cell adhesion, consistent with a "TNF tolerance" anti-inflammatory mechanism.[¹] Among this family, Chonluten's clearest reported signal is this anti-inflammatory effect on immune cells.

Evidence quality. Preclinical (cell-line). There are no large controlled human trials. See the shared Khavinson caveat below.

### About the Khavinson bioregulators (shared framing)

The bioregulator / cytomedin/cytogen peptides were developed from the 1970s by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. Original "cytomedins" were organ-extract peptide complexes; the newer "cytogens" are synthetic short peptides proposed to have tissue-specific effects on the organ they derive from, under the group's "peptide theory of ageing."[²] Honest caveats: the evidence is overwhelmingly preclinical plus small, often non-blinded Russian studies; there are no large independent randomized trials; none are FDA-approved; and they are sold in Russia as injectables and supplements. Treat as an unproven research tradition.

Regulatory status (US). Not FDA-approved; not a drug. Not DEA-scheduled.

Regulatory status (sport — WADA). Not specifically named; best treated as S0 (non-approved), prohibited at all times. Verify with your anti-doping organization.

Common research interests. Airway/lung and anti-inflammatory support (its associated tissue and its clearest preclinical signal). Extrapolated from cell data, not an established human use.

Commonly reported

• Injection-site reactions
• Reactions to research-supply material of variable purity
• Immune modulation. Chonluten alters immune-cell inflammatory signaling in vitro;[¹] the consequences of modulating immune signaling in humans are uncharacterized.
• Unknown long-term safety.

Not a treatment for any inflammatory or lung condition — see a clinician

Pregnancy and lactation — no data; default to contraindicated

Pediatric use — no data; not for researchers under 18

Active infection / immune disease — caution given the immune-modulating signal

Known hypersensitivity — contraindicated

Regulatory note (US): Not FDA-approved; not DEA-scheduled.

Regulatory note (sport): Best treated as WADA S0. Verify with your anti-doping organization.

Bioregulator (Khavinson peptide)

A very short synthetic peptide from the St. Petersburg Institute of Bioregulation and Gerontology, each linked to an organ.

TNF (tumor necrosis factor)

A signaling molecule that drives inflammation. Chonluten reduced TNF release from immune cells in the lab.

Monocyte / macrophage

Immune cells involved in inflammation; the cells used in the Chonluten study.

Preclinical

Research in cells or animals, before human testing.

1. Avolio F, Martinotti S, Khavinson VKh, Esposito JE, Giambuzzi G, Marino A, Mironova E, et al. (2022). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences, 23(7):3607.(PMID 35408963)
2. Khavinson VKh. (2002). Peptides and Ageing. Neuro Endocrinology Letters, 23 Suppl 3:11–144.(PMID 12374906)

• Bronchogen — same mechanism class
• Cardiogen — same mechanism class
• Cartalax — same mechanism class
• Cortagen — same mechanism class
• Crystagen — same mechanism class
• Epitalon — same mechanism class